Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback